# Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.

> **NCT03869892** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Institut de Recherches Internationales Servier** · enrollment: 856 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Trifluridine/tipiracil hydrochloride (S95005)
- **DRUG:** Capecitabine
- **BIOLOGICAL:** Bevacizumab experimental
- **BIOLOGICAL:** Bevacizumab control

## Key facts

- **NCT ID:** NCT03869892
- **Lead sponsor:** Institut de Recherches Internationales Servier
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-03-21
- **Primary completion:** 2021-06-29
- **Final completion:** 2026-12-31
- **Target enrollment:** 856 (ACTUAL)
- **Last updated:** 2025-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03869892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03869892, "Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03869892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*